Overview

* Quanterix Q2 2025 revenue falls 29% yr/yr, net loss widens significantly

* Company completed acquisition of Akoya Biosciences, aiming for cash flow breakeven by 2026

* Alzheimer's Diagnostics revenues more than tripled yr/yr, despite market challenges

Outlook

* Quanterix ( QTRX ) expects full-year 2025 revenue between $130 mln and $135 mln

* Quanterix ( QTRX ) projects GAAP gross margin of 49% to 53% for 2025

* Company aims for cash flow breakeven in 2026

Result Drivers

* AKOYA COMBINATION - Quanterix ( QTRX ) cites combination with Akoya Biosciences as creating high-margin, high-throughput business

* ALZHEIMER'S DIAGNOSTICS - Alzheimer's Diagnostics revenues more than tripled yr/yr, indicating strong demand

* ACCELERATOR BUSINESS - Net increase in new customers despite smaller project sizes due to constrained biopharma budgets

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 $16.83

Product mln

Revenue

Q2 Net -$30.01

Income mln

Q2 Basic -$0.77

EPS

Q2 Gross $11.30

Profit mln

Q2 $48.40

Operatin mln

g

Expenses

Q2 -$37.10

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

* Wall Street's median 12-month price target for Quanterix Corp ( QTRX ) is $8.00, about 29.9% above its August 6 closing price of $5.61

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)